In an 88‑year‑old woman with atrial fibrillation, coronary artery disease, hypertension, dyslipidemia, heart‑failure with preserved ejection fraction, chronic kidney disease stage III, gastro‑oesophageal reflux disease, and osteoporosis who was hospitalized for acute decompensated heart failure and rapid‑ventricular‑response atrial fibrillation but is now euvolemic and rate‑controlled, should she undergo catheter ablation or can amiodarone be discontinued while continuing metoprolol for rate control?

Rate Control with Metoprolol is the Appropriate Strategy; Discontinue Amiodarone and Do Not Pursue Ablation

In this 88-year-old woman with HFpEF who is now euvolemic and rate-controlled, you should continue metoprolol for rate control and discontinue amiodarone—catheter ablation is not appropriate given her age and clinical profile.

Rationale Against Ablation in This Patient

The 2019 European Heart Journal guidelines explicitly state that catheter ablation may not be appropriate in patients at advanced age, with extensive atrial remodeling, or poor functional status 1. The evidence supporting ablation comes primarily from trials like CASTLE-AF, which had "distinct selection bias towards younger and less severely affected patients with lower peri-procedural risk profile" 1. At 88 years old with multiple comorbidities (CAD, CKD stage III, HFpEF), this patient falls well outside the population that has demonstrated benefit from ablation.

Furthermore, the guideline recommendations for ablation (Class IIa-B) apply specifically to HFrEF (heart failure with reduced ejection fraction), not HFpEF 1. Your patient has HFpEF, where the evidence for ablation benefit is substantially weaker and not guideline-supported for routine use.

Why Continue Metoprolol and Discontinue Amiodarone

Metoprolol Should Be Continued

• Rate control is the primary goal in an elderly patient with permanent/persistent AF who is now rate-controlled and euvolemic
• The FDA label confirms metoprolol's role in managing AF with rate control, though it warns about heart failure exacerbation 2
• Since she is currently euvolemic and rate-controlled, metoprolol is achieving its therapeutic goal without causing decompensation
• The 2024 ACC/AHA guidelines note that amiodarone is the only antiarrhythmic that doesn't require dose adjustment in CKD 3, but this doesn't mean it should be continued indefinitely when rate control alone is sufficient

Amiodarone Should Be Discontinued

Amiodarone has no role in long-term management once rate control is achieved, especially in elderly patients with multiple comorbidities:

• Amiodarone is indicated for rhythm control, not rate control 4
• The 2019 guidelines state that amiodarone continuation after achieving stable rhythm "is arguable" and should be reconsidered, particularly noting that "continuation of AAD therapy after catheter ablation in order to improve AF-free survival is arguable" 1
• The FDA label details extensive drug interactions and toxicities with chronic amiodarone use, including interactions with her likely medications (statins, anticoagulants, other cardiovascular drugs) 4
• A 2024 case report specifically describes an HFpEF patient with AF where discontinuing amiodarone led to marked improvement in exercise capacity, reduction in NT-proBNP, and reverse remodeling 5

Practical Management Algorithm

Step 1: Confirm Rate Control Adequacy

• Target resting heart rate 60-100 bpm (lenient control acceptable in elderly)
• Assess for symptoms: palpitations, dyspnea, exercise intolerance
• If adequately rate-controlled and asymptomatic → proceed to Step 2

Step 2: Discontinue Amiodarone

• Taper is not strictly required for amiodarone discontinuation in the absence of ventricular arrhythmias
• Monitor for AF with RVR recurrence over 2-4 weeks (amiodarone has long half-life)

Step 3: Optimize Metoprolol Dosing

• Continue current dose if rate control maintained
• Critical caveat: Monitor for chronotropic insufficiency, especially in HFpEF patients where exercise capacity depends on heart rate response 5
• If symptomatic bradycardia or exercise intolerance develops, consider dose reduction

Step 4: Ensure Anticoagulation

• Continue anticoagulation indefinitely (CHA₂DS₂-VASc score clearly elevated)
• With CKD stage III, DOACs are preferred over warfarin per 2024 guidelines 3
• Dose-adjust DOAC appropriately for renal function

Step 5: Optimize HFpEF Management

• Ensure SGLT2 inhibitor is prescribed (strongest evidence for HFpEF outcomes)
• Consider other guideline-directed medical therapy for HFpEF
• Manage volume status with diuretics as needed

Key Caveats and Pitfalls

Do not abruptly stop metoprolol due to her coronary artery disease—the FDA label explicitly warns of severe exacerbation of angina, MI, and ventricular arrhythmias with abrupt beta-blocker discontinuation in CAD patients 2.

Watch for chronotropic insufficiency after amiodarone discontinuation, particularly in HFpEF where cardiac output depends heavily on heart rate during exertion 5. If exercise intolerance develops despite rate control, metoprolol dose reduction may be needed.

Avoid the temptation to pursue rhythm control in this elderly patient. The 2019 guidelines emphasize that rhythm control strategies (including ablation) should be "geared to those HF populations included in previous RCTs"—which excluded patients of this age and complexity 1.

Monitor renal function closely given CKD stage III and polypharmacy. Both metoprolol and amiodarone can affect renal perfusion, though amiodarone doesn't require renal dose adjustment 3.